RESULT UPDATE

KEY DATA

Rating	HOLD
Sector relative	Neutral
Price (INR)	1,087
12 month price target (INR)	935
52 Week High/Low	1,091/440
Market cap (INR bn/USD bn)	98/1.1
Free float (%)	25.2
Avg. daily value traded (INR mn)	537.9

SHAREHOLDING PATTERN

	Jun-25	Mar-25	Dec-24
Promoter	74.82%	74.82%	74.82%
FII	5.48%	4.69%	3.77%
DII	9.38%	10.28%	10.07%
Pledge	0%	0%	0%

FINANCIALS (INR mn) Year to March FY25A FY26E FY27E FY28E Revenue 43,199 49,009 55,079 62,384 **EBITDA** 6.135 8.675 10.300 11.978 Adjusted profit 3.044 4.228 5.351 6.060 Diluted EPS (INR) 46.9 59.3 67.2 33.7 853.8 38.9 26.6 13.3 EPS growth (%) RoAE (%) 12.9 15.8 17.3 16.8 32.2 23.2 18.3 16.2 P/E (x) EV/EBITDA (x) 15.6 11.2 9.3 7.8 Dividend yield (%)

CHANGE IN ESTIMATES

	Revised estimates		% Revi	sion
Year to March	FY26E	FY27E	FY26E	FY27E
Revenue	49,009	55,079	0.0%	1.6%
EBITDA	8,675	10,300	12.7%	13.7%
Adjusted profit	4,228	5,351	19.3%	27.9%
Diluted EPS (INR)	46.9	59.3	19.3%	27.9%

PRICE PERFORMANCE



Promising yet unsustainable start

Sharda Cropchem's healthy earnings print in Q1FY26 was supported by a gradual recovery in global demand, normalising inventory levels in the channel and favourable pricing in key markets such as Europe. Sharda reported sales/EBITDA/PAT growth of 25.4%/179.4%/424.0% YoY beating all headline estimates.

As we rollover estimates to FY28E, we find Sharda's valuations quite stretched after a sharp rally post-results. The stock is trading at 16x FY28E EPS and 18x FY27E EPS, which we believe is high given Sharda's cyclical business. Hence, we downgrade the stock to 'HOLD' from 'BUY' as we transition to 7x EV/EBITDA valuation based on Q1FY28E, yielding a revised target price of INR935/share (earlier INR774).

Europe outperformance continues

Volumes in the agrochem business grew 11% YoY led by strong volume growth in Europe of 31.3%. Gross margin in the European region was surprisingly high (highest so far) at 43%, up 8pp. This subsequently drove blended GM to 35.5% (up 630bp YoY). Management expects GM to sustain, which we believe has historically been transient; maintaining 35%-plus GM seems challenging. The company also expects EBITDA margin to be in the range of 15-18%. Sharda continues to maintain a healthy registration pipeline. We note that despite having more than 2,000 products registered in different geographies, the top ten products contribute to a lion's share of revenue to the tune of 36%. The company also benefitted from a favourably stronger euro (as the euro appreciated against the dollar over the last six months), accruing 12% foreign exchange benefit, which also boosted profitability. We find these arguments temporary for Sharda Cropchem to sustainably grow or maintain the prevailing margins. Growth in the non-agrochemicals business was volume-led. It grew 58.5% YoY, especially in NAFTA by 36% YoY, possibly due to frantic buying behaviour amid tariff uncertainty.

Downgrade to 'HOLD' after sharp rally

Sharda's solid performance led to a sharp rally in the stock, surpassing our TP in only a quarter. We believe Sharda's business model undergoes vagaries caused by global agriculture and currency fluctuations, which may be recovering at this point. Hence, we refrain from ascribing a higher target multiple to the stock given the earnings cyclicality. That said, the company maintained its growth guidance despite significant growth in Q1FY26. This may warrant a moderation in quarterly earnings going forward. We also believe that the said growth for FY25-28E is more than priced in. Hence, we downgrade to 'HOLD' and await a better price point to enter the stock.

Financials

Year to March	Q1FY26	Q1FY25	% Change	Q4FY25	% Change
Net Revenue	9,848	7,851	25.4	18,285	(46.1)
EBITDA	2,153	770	179.4	3,032	(29.0)
Adjusted Profit	1,428	273	424.0	2,036	(29.9)
Diluted EPS (INR)	15.8	3.0	424.0	22.6	(29.9)

Archit Joshi Archit.Joshi@nuvama.com Rohan Ohri rohan.ohri@nuvama.com

Financial Statements

Income Statement (INR mn)

Year to March	FY25A	FY26E	FY27E	FY28E
Total operating income	43,199	49,009	55,079	62,384
Gross profit	12,918	16,173	18,176	20,587
Employee costs	520	637	716	811
Other expenses	6,263	6,861	7,160	7,798
EBITDA	6,135	8,675	10,300	11,978
Depreciation	2,747	3,616	3,774	4,538
Less: Interest expense	21	29	29	29
Add: Other income	595	607	638	669
Profit before tax	3,783	5,637	7,134	8,080
Prov for tax	739	1,409	1,784	2,020
Less: Other adj	0	0	0	0
Reported profit	3,044	4,228	5,351	6,060
Less: Excp.item (net)	0	0	0	0
Adjusted profit	3,044	4,228	5,351	6,060
Diluted shares o/s	90	90	90	90
Adjusted diluted EPS	33.7	46.9	59.3	67.2
DPS (INR)	6.0	7.0	7.0	7.0
Tax rate (%)	19.5	25.0	25.0	25.0

Balance Sheet (INR mn)

Year to March	FY25A	FY26E	FY27E	FY28E
Share capital	902	902	902	902
Reserves	24,103	27,700	32,419	37,847
Shareholders funds	25,006	28,602	33,321	38,750
Minority interest	4	4	4	4
Borrowings	0	0	0	0
Trade payables	13,102	14,904	16,750	18,971
Other liabs & prov	8,493	8,489	9,254	10,174
Total liabilities	47,249	52,642	59,972	68,542
Net block	7,432	9,242	10,304	10,766
Intangible assets	0	4	4	4
Capital WIP	2,914	2,914	2,914	2,914
Total fixed assets	10,346	12,160	13,222	13,684
Non current inv	0	0	0	0
Cash/cash equivalent	2,203	649	2,269	4,914
Sundry debtors	19,554	22,155	24,899	28,201
Loans & advances	0	0	0	0
Other assets	15,073	17,677	19,580	21,742
Total assets	47,249	52,642	59,972	68,542

Important Ratios (%)

Year to March	FY25A	FY26E	FY27E	FY28E
Europe growth(%)	42.1	13.1	12.1	13.1
NAFTA growth(%)	41.4	13.5	12.7	13.5
LATAM growth(%)	28.0	17.4	12.6	13.4
EBITDA margin (%)	14.2	17.7	18.7	19.2
Net profit margin (%)	7.0	8.6	9.7	9.7
Revenue growth (% YoY)	36.6	13.5	12.4	13.3
EBITDA growth (% YoY)	116.9	41.4	18.7	16.3
Adj. profit growth (%)	853.8	38.9	26.6	13.3

Free Cash Flow (INR mn)

	,			
Year to March	FY25A	FY26E	FY27E	FY28E
Reported profit	3,044	4,228	5,351	6,060
Add: Depreciation	2,747	3,616	3,774	4,538
Interest (net of tax)	21	29	29	29
Others	378	(142)	(225)	(142)
Less: Changes in WC	279	(3,195)	(1,812)	(2,181)
Operating cash flow	6,469	4,536	7,117	8,305
Less: Capex	(3,326)	(5,430)	(4,836)	(5,000)
Free cash flow	3,143	(894)	2,281	3,305

Assumptions (%)

Year to March	FY25A	FY26E	FY27E	FY28E
GDP (YoY %)	6.5	6.0	6.5	6.5
Repo rate (%)	6.3	5.0	5.0	5.0
USD/INR (average)	84.6	86.5	86.0	86.0
ROW growth(%)	(11.7)	13.5	12.7	13.5
Tax rate(%)	19.5	25.0	25.0	25.0
Capex (INR mn)	(3,326.2)	(5,430.1)	(4,835.9)	(5,000.0)
Agrochem mix(%)	87.4	87.2	86.9	86.7
Non-Agrochem mix(%)	12.6	12.8	13.1	13.3

Key Ratios

Year to March	FY25A	FY26E	FY27E	FY28E
RoE (%)	12.9	15.8	17.3	16.8
RoCE (%)	16.8	21.1	23.1	22.5
Inventory days	118	121	127	126
Receivable days	146	155	156	155
Payable days	134	156	157	156
Working cap (% sales)	32.0	34.7	34.2	33.6
Gross debt/equity (x)	0	0	0	0
Net debt/equity (x)	(0.1)	0	(0.1)	(0.1)
Interest coverage (x)	160.9	174.4	225.0	256.5

Valuation Metrics

Year to March	FY25A	FY26E	FY27E	FY28E
Diluted P/E (x)	32.2	23.2	18.3	16.2
Price/BV (x)	3.9	3.4	2.9	2.5
EV/EBITDA (x)	15.6	11.2	9.3	7.8
Dividend yield (%)	0.6	0.6	0.6	0.6

Source: Company and Nuvama estimates

Valuation Drivers

Year to March	FY25A	FY26E	FY27E	FY28E
EPS growth (%)	853.8	38.9	26.6	13.3
RoE (%)	12.9	15.8	17.3	16.8
EBITDA growth (%)	116.9	41.4	18.7	16.3
Payout ratio (%)	17.8	14.9	11.8	10.4

Exhibit 1: Quarterly financial snapshot (INR mn)

								INR mn
Year to March	Q1FY26	Q1FY25	% change	Q4FY25	% change	FY26E	FY27E	FY28E
Revenue	9,848	7,851	25.4	18,285	(46.1)	49,009	55,079	62,384
Raw material costs	6,356	5,562	14.3	12,845	(50.5)	32,836	36,903	41,797
Gross profit	3,492	2,289	52.6	5,440	(35.8)	16,173	18,176	20,587
Employee costs	149	112	33.9	182	(18.1)	637	716	811
Other expenses	1,190	1,407	(15.4)	2,226	(46.6)	6,861	7,160	7,798
Total operating expenses	1,339	1,518	(11.8)	2,409	(44.4)	7,498	7,876	8,609
EBITDA	2,153	770	179.4	3,032	(29.0)	8,675	10,300	11,978
Depreciation	781	648	20.5	719	8.6	3,616	3,774	4,538
EBIT	1,372	123	1,018.9	2,313	(40.7)	5,059	6,526	7,440
Less: Interest Expense	6	8	(27.1)	4	36.6	29	29	29
Add : Other Income	325	193	68.4	252	28.7	607	638	669
Add: Prior Period items								
Profit Before Tax	1,691	308	449.4	2,561	(34.0)	5,637	7,134	8,080
Less: Provision for Tax	263	35	645	525	(49.8)	1,409	1,784	2,020
Reported Profit	1,428	273	424.0	2,036	(29.9)	4,228	5,351	6,060
Adjusted Profit	1,428	273	424.0	2,036	(29.9)	4,228	5,351	6,060
Equity capital (FV INR 10)	902	902	0.0	902	0.0	902	902	902
No. of Diluted shares outstanding (mn)	90	90	0.0	90	0.0	90	90	90
Adjusted Diluted EPS	15.8	3.0	424.0	22.6	(29.9)	46.9	59.3	67.2
As % of revenues								
cogs	64.5	70.8		70.2		67.0	67.0	67.0
Gross profit	35.5	29.2	630.5	29.8	570.5	33.0	33.0	33.0
Employee costs	1.5	1.4		1.0		1.3	1.3	1.3
Other expenses	12.1	17.9		12.2		14.0	13.0	12.5
Total operating expenses	13.6	19.3		13.2		15.3	14.3	13.8
EBITDA	21.9	9.8	1204.8	16.6	528.0	17.7	18.7	19.2
Net profit	14.5	3.5		11.1		8.6	9.7	9.7

Source: Company, Nuvama Research

Company Description

SCC is a crop protection chemical company marketing and distributing a wide range of formulations and active ingredients globally. It also procures and supplies belts, general chemicals, dyes and dye intermediates. The company commenced operations via 2 sole proprietary firms, each set up by Mr. Ramprakash V. Bubna and Ms. Sharda R. Bubna. After incorporation as Sharda Worldwide Exports in 2004, the generic agrochemical and nonagrochemical businesses carried out by both the firms were transferred to the company. The company's name was changed to Sharda Cropchem and it was converted into a public limited company in FY14.

Investment Theme

SCC pursues a differentiated asset-light business model underpinned by focus on product registrations. SCC is on cusp of exponential surge riding multiple triggers—rising wallet share in existing products and new launches further bolstered by expansion of in-house sales team. We perceive re-rating potential in light of strong product registration led growth, net cash balance sheet and return ratios.

Key Risks

Weather: The crop protection industry has to contend with the vagaries of nature. Inclement weather can trigger pest infestations as well as affect demand for crop protection products. Adverse weather conditions in SCC's regions will negatively affect the company's sales. Further, delayed or adverse monsoon could negatively affect collection of receivables. However, we believe SCC has presence in over 76 countries which minimises country specific risk and its impact on overall financials. Genetically modified (GM) crops: The use of crop protection products is significantly less for GM crops. Hence, growth and acceptance of GM crops by consumers may adversely affect SCC's business. Adverse currency movement: SCC deals in multiple currencies across geographies. Ergo, any sharp movement could impact the company's earnings adversely. Further, its relatively long receivables cycle enhances the currency volatility risk. However, we believe it can pass on the impact to customers to some extent with a lag. Moreover, SCC's sales and purchases are in EUR/ USD and USD, respectively. Hence, it provides natural hedge to significant extent. However, we see major currency risk in term of EUR-USD movement

Additional Data

Management

MD	Ramprakash V. Bubna
WTD	Ashish Bubna
WTD	Manish Bubna
ED	
Auditor	B S R & Associates LLP

Recent Company Research

Date	Title	Price	Reco
15-May-25	Strong volume growth; <i>Result Update</i>	613	Buy
24-Jan-25	Volumes and margins both improve ; Result Update	725	Buy
28-Oct-24	Margin expansion to continue; Result Update	653	Buy

Holdings – Top 10*

	% Holding		% Holding
HDFC Asset Mana	6.93	Motilal oswal A	0.08
DSP Investment	2.14	Wisdom tree	0.07
Dimensional Fun	0.57	American centur	0.05
Tata AMC	0.15	AXA SA	0.02
State street co	0.09	Samco Asset man	0.02

^{*}Latest public data

Recent Sector Research

Date	Name of Co./Sector	Title
15-Jul-25	Rallis India	All-round beat; Result Update
07-Jul-25	Agri Inputs	Raining good news: Strong start to Khari; Sector Update
16-May-25	Dhanuka Agritech	Double-digit growth poised to continue; Result Update

Rating and Daily Volume Interpretation



Source: Bloomberg, Nuvama research

Rating Rationale & Distribution: Nuvama Research

8				
Rating	Expected absolute returns over 12 months	Rating Distribution		
Buy	15%	202		
Hold	<15% and >-5%	66		
Reduce	<-5%	36		

DISCLAIMER

Nuvama Wealth Management Limited (defined as "NWML" or "Research Entity") a company duly incorporated under the Companies Act, 1956 (CIN No L67110MH1993PLC344634) having its Registered office situated at 801- 804, Wing A, Building No. 3, Inspire BKC, G Block, Bandra Kurla Complex, Bandra East, Mumbai – 400 051 is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, Investment Adviser, Research Analyst and other related activities. Name of Compliance/Grievance officer: Mr. Atul Bapna, E-mail address: complianceofficer.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mailto:

This Report has been prepared by NWML in the capacity of a Research Analyst having SEBI Registration No.INH000011316 and Enlistment no. 5723 with BSE and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Securities as defined in clause (h) of section 2 of the Securities Contracts (Regulation) Act, 1956 includes Financial Instruments and Currency Derivatives. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in Securities referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NWML and associates, subsidiaries / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. NWML reserves the right to make modifications and alterations to this statement as may be required from time to time. NWML or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NWML is committed to providing independent and transparent recommendation to its clients. Neither NWML nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future p

NWML shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the NWML to present the data. In no event shall NWML be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the NWML through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

NWML and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the Securities, mentioned herein or (b) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. (c) NWML may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. (d) The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with NWML (e) Registration granted by SEBI and certification from NISM in no way guarantee performance of NWML or provide any assurance of returns to investors and clients.

NWML or its associates may have received compensation from the subject company in the past 12 months. NWML or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. NWML or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWML or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWML or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or NWML's associates may have financial interest in the subject company. NWML and/or its Group Companies, their Directors, affiliates and/or employees may have interests/ positions, financial or otherwise in the Securities/Currencies and other investment products mentioned in this report. NWML, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No

NWML has financial interest in the subject companies: No

NWML's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

NWML has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by NWML on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at www.nseindia.com

Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Additional Disclaimers

Disclaimer for U.S. Persons

This research report is a product of NWML, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by NWML only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, NWML has entered into an agreement with a U.S. registered broker-dealer, Nuvama Financial Services Inc. (formerly Edelweiss Financial Services Inc.) ("NFSI"). Transactions in securities discussed in this research report should be effected through NFSI.

Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA").

In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

Disclaimer for Canadian Persons

This research report is a product of NWML, which is the employer of the research analysts who have prepared the research report. The research analysts preparing the research report are resident outside the Canada and are not associated persons of any Canadian registered adviser and/or dealer and, therefore, the analysts are not subject to supervision by a Canadian registered adviser and/or dealer, and are not required to satisfy the regulatory licensing requirements of the Ontario Securities Commission, other Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and are not required to otherwise comply with Canadian rules or regulations regarding, among other things, the research analysts' business or relationship with a subject company or trading of securities by a research analyst.

This report is intended for distribution by NWML only to "Permitted Clients" (as defined in National Instrument 31-103 ("NI 31-103")) who are resident in the Province of Ontario, Canada (an "Ontario Permitted Client"). If the recipient of this report is not an Ontario Permitted Client, as specified above, then the recipient should not act upon this report and should return the report to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any Canadian person.

NWML is relying on an exemption from the adviser and/or dealer registration requirements under NI 31-103 available to certain international advisers and/or dealers. Please be advised that (i) NWML is not registered in the Province of Ontario to trade in securities; (ii) NWML's head office or principal place of business is located in India; (iii) all or substantially all of NWML's assets may be situated outside of Canada; (iv) there may be difficulty enforcing legal rights against NWML because of the above; and (v) the name and address of the NWML's agent for service of process in the Province of Ontario is: Bamac Services Inc., 181 Bay Street, Suite 2100, Toronto, Ontario MSJ 273 Canada.

Disclaimer for Singapore Persons

In Singapore, this report is being distributed by Nuvama Investment Advisors Private Limited (NIAPL) (Previously Edelweiss Investment Advisors Private Limited ("EIAPL")) (Co. Reg. No. 201016306H) which is a holder of a capital markets services license and an exempt financial adviser in Singapore and (ii) solely to persons who qualify as "institutional investors" or "accredited investors" as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Pursuant to regulations 33, 34, 35 and 36 of the Financial Advisers Regulations ("FAR"), sections 25, 27 and 36 of the Financial Advisers Act, Chapter 110 of Singapore shall not apply to NIAPL when providing any financial advisory services to an accredited investor (as defined in regulation 36 of the FAR. Persons in Singapore should contact NIAPL in respect of any matter arising from, or in connection with this publication/communication. This report is not suitable for private investors.

Disclaimer for Hong Kong persons

This report is distributed in Hong Kong by Nuvama Investment Advisors (Hong Kong) Private Limited (NIAHK) (Previously Edelweiss Securities (Hong Kong) Private Limited (ESHK)), a licensed corporation (BOM -874) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to Section 116(1) of the Securities and Futures Ordinance "SFO". This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The report also does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of any individual recipients. The Indian Analyst(s) who compile this report is/are not located in Hong Kong and is/are not licensed to carry on regulated activities in Hong Kong and does not / do not hold themselves out as being able to do so.

INVESTMENT IN SECURITIES MARKET ARE SUBJECT TO MARKET RISKS. READ ALL THE RELATED DOCUMENTS CAREFULLY BEFORE INVESTING.

Abneesh Roy Head of Research Committee Abneesh.Roy@nuvama.com